Direct to consumer pharmaceutical marketing
Download
1 / 9

Direct-to-Consumer Pharmaceutical Marketing - PowerPoint PPT Presentation


  • 99 Views
  • Uploaded on

http://www.sfubiz.ca/sma/wp-content/uploads/2013/04/DTC-Advertising-EN.sflb_. jpg. http://www.havidol.com/images/content_female.jpg. Direct-to-Consumer Pharmaceutical Marketing. Power Point by Joshua Friesen. http://pharmaregulations.files.wordpress.com/2010/10/wizardofid20522440207231.gif.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' Direct-to-Consumer Pharmaceutical Marketing' - eudora


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Direct to consumer pharmaceutical marketing

http://www.sfubiz.ca/sma/wp-content/uploads/2013/04/DTC-Advertising-EN.sflb_.http://www.sfubiz.ca/sma/wp-content/uploads/2013/04/DTC-Advertising-EN.sflb_.jpg

http://www.havidol.com/images/content_female.jpg

Direct-to-Consumer Pharmaceutical Marketing

Power Point by Joshua Friesen

http://pharmaregulations.files.wordpress.com/2010/10/wizardofid20522440207231.gif


How can DTCPA be reformed so as to make it a beneficial practice for patients?

But why does it need to be reformed?

http://lifecarechiropractic.com/blog/wp-content/uploads/2012/09/vioxx-news-risk-of-having-heart-attack.png


FDA practice for patients?

  • Under staffed

  • Low funding

  • Complicated red tape

http://www.thedailyrant.us/FDA.gif

  • FDA Regulation

  • Not be false or misleading

  • Present a “fair balance” of information

  • Include facts

  • Brief Summary



>55,000 DEATHS practice for patients?

http://www.nature.com/nature/journal/v436/n7050/images/436459a-i2.0.jpg

http://www.healthnewsreview.org/wp-content/uploads/2012/02/27176791.jpg

$321 million fine

$4.85 billion payout to patients

http://www.negotiationlawblog.com/uploads/image/vioxx%20settlement%20forum.jpg


Delay advertising for new products
Delay Advertising for New Products practice for patients?

  • Special symbol the first two years a drug is on the market

  • Delayed advertising until full drug safety profile is complete

  • Clinical trials are not designed to detect rare adverse effects

  • Blockbuster sellers are promoted early in their life


Ban qualifying language in dtc
Ban Qualifying practice for patients?Language in DTC

“Relapanaxis generally very well tolerated. Side effects tend to be mild and often go away in a short time. If side effects do occur they may include: nausea, upset stomach and diarrhea. It is important for you to know that few people were bothered enough by these side effects to stop taking Relapanax.””

“The most common side effects were headache (3%) and stomach ache (2%). Side effects generally did not last for a long time. All side effects disappeared within two weeks. Very few people (1%) stopped taking Relapanax due to these side effects.’’

http://www.hightowerlowdown.org/sites/hightowerlowdown.civicactions.net/files/2012-05_cartoon.jpg


Require pre clearance by the fda
Require Pre-clearance by the practice for patients?FDA

  • Mandatory preclearance procedure

  • Pay user fees

  • Increase resources of FDA

  • Regulation of online advertising

http://stuartbramhall.files.wordpress.com/2014/01/big-pharma.jpg?w=614

  • 50% though ads had to be approved by government

  • 43% though medication had to be completely safe to be advertised

  • 22% though that drugs known to have serious side effects couldn’t be advertised


Work cited
Work Cited practice for patients?

Davis, Joel. "The Effect of Qualifying Language on Perceptions of Drug Appeal, Drug Experience, and Estimates of Side-Effect Incidence in DTC Advertising." Journal of Health Communications. 12.1 (2007): 607- 622. Web.

Johar, Kanika. "An Insider's Perspective: Defense of the Pharmaceutical Industry's MarketingPractices." Albany Law Review. 76.1 (2013): 299- 334. Web.

Ventola, Lee. "Direct-to-Consumer Pharmaceutical Advertising Therapeutic or Toxic." P&T. 36.10 (2011): 669-84. Web.


ad